Ask a doctor about a prescription for HIRUDOID 3 mg/g GEL
PACKAGE LEAFLET: INFORMATION FOR THE USER
Hirudoid 3 mg/g gel
Sodium chondroitin sulfate
Read the package leaflet carefully before starting to use this medicine, as it contains important information for you.
Follow the instructions for administration of the medicine contained in this package leaflet or as indicated by your doctor or pharmacist.
Contents of the package leaflet:
Hirudoid is a medicine that contains sodium chondroitin sulfate as the active ingredient and has properties that favor blood flow.
This medicine is indicated for:
local symptomatic relief of superficial venous disorders such as heaviness and tightness in legs with varices in adults
local symptomatic relief of superficial hematomas caused by blows in adults and children over 1 year of age.
You should consult a doctor if it worsens or does not improve after 5 days.
Do not use Hirudoid
Warnings and precautions
Consult your doctor or pharmacist before starting to use Hirudoid.
In case of venous problems caused by blood clots (such as thromboembolism, obstruction of a blood vessel that hinders blood flow), it is recommended to apply the product gently and without massage.
Using Hirudoid with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medicine.
It is not recommended to apply other topical preparations to the same area without consulting your doctor.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
You should not use Hirudoid during pregnancy or breastfeeding unless your doctor advises you to do so.
Driving and using machines
No effects on the ability to drive vehicles or use machinery have been described.
Hirudoid contains propylene glycol
This medicine contains 5 mg of propylene glycol per gram of gel. Propylene glycol may cause skin irritation.
This medicine contains propylene glycol; do not use on open wounds or large areas of damaged skin (such as burns) without consulting your doctor or pharmacist first.
Follow the instructions for administration of the medicine contained in this package leaflet or as indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist.
This medicine is for topical use (exclusively on the skin). The recommended dose is:
Superficial venous disorders
Adults:apply a thin layer of gel or ointment to the affected area 2 to 3 times a day, distributing it with a gentle massage to facilitate penetration.
Wash your hands after each application to avoid unintentional contact with eyes and mucous membranes.
The average duration of treatment is usually between 1 and 2 weeks. If symptoms worsen or persist after 5 days of treatment, you should consult a doctor.
Children under 18 years:do not use without medical supervision.
Hematomas:
Adults and children over 1 year:apply a thin layer of gel or ointment to the affected area 2 to 3 times a day, distributing it with a gentle massage to facilitate penetration.
Wash your hands after each application to avoid unintentional contact with eyes and mucous membranes. The average duration of treatment for hematomas is usually less than 10 days. If symptoms worsen or persist after 5 days of treatment, you should consult a doctor. Children under 1 year:do not use without medical supervision.
If you use more Hirudoid than you should
If you have used more Hirudoid than you should or in case of accidental ingestion, consult the Toxicology Information Service. Telephone 91 562 04 20, indicating the medicine and the amount ingested.
Accidental ingestion of large amounts of Hirudoid gel due to its content of isopropyl alcohol may cause symptoms of acute alcohol intoxication.
In case of possible alcohol intoxication, special therapeutic measures should be initiated immediately.
If you forget to use Hirudoid
Do not apply a double dose to make up for forgotten doses.
You should continue treatment as normal without taking any particular action.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Hirudoid can cause side effects, although not everybody gets them.
It has been observed that very rarely (affects less than 1 in 10,000 patients), allergic reactions may appear at the application site, which can manifest as itching and irritation, and which disappear when treatment is discontinued.
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the national reporting system included in the Spanish Medicines Monitoring System for Human Use Website: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after CAD. The expiry date is the last day of the month indicated.
You should discard the tube 12 months after first opening. Write the opening date in the space provided on the carton.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines in the SIGRE collection point at your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Hirudoid
Appearance of the product and contents of the pack
Hirudoid is available in lacquered aluminum tubes with 40 grams of gel.
Marketing authorization holder
Laboratory STADA S.L. Frederic Mompou, 5
08960 Sant Just Desvern (Spain) info@stada.es
Manufacturer
Mobilat Produktions GmbH Luitpoldstrasse 1
85276 Pfaffenhofen Germany
or
STADA Arzneimittel AG Stadastrasse 2-18
61118 - Bad Vilbel
Germany
Date of last revision of this package leaflet: September 2021
“Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/”
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for HIRUDOID 3 mg/g GEL – subject to medical assessment and local rules.